Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - AVADEL PHARMACEUTICALS PLC | avdlex-312.htm |
| EX-32.2 - EXHIBIT 32.2 - AVADEL PHARMACEUTICALS PLC | avdlex-322.htm |
| EX-32.1 - EXHIBIT 32.1 - AVADEL PHARMACEUTICALS PLC | avdlex-321.htm |
| EX-31.1 - EXHIBIT 31.1 - AVADEL PHARMACEUTICALS PLC | avdlex-311.htm |
| EX-23.1 - EXHIBIT 23.1 - AVADEL PHARMACEUTICALS PLC | avdlex-231.htm |
| EX-21.1 - EXHIBIT 21.1 - AVADEL PHARMACEUTICALS PLC | avdlex-211.htm |
| EX-10.46 - EXHIBIT 10.46 - AVADEL PHARMACEUTICALS PLC | avdlex-1046.htm |
| EX-10.45 - EXHIBIT 10.45 - AVADEL PHARMACEUTICALS PLC | avdlex-1045.htm |
| EX-10.44 - EXHIBIT 10.44 - AVADEL PHARMACEUTICALS PLC | avdlex-1044.htm |
| EX-10.43 - EXHIBIT 10.43 - AVADEL PHARMACEUTICALS PLC | avdlex-1043.htm |
| 10-K - 10-K - AVADEL PHARMACEUTICALS PLC | avdl201710k.htm |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No.’s 333-213154, 333-212585, 333-177591 and 333-219016 on Form S-8 and 333-183961 on Form S-3 of our reports dated March 16, 2018, relating to the consolidated financial statements and financial statement schedule of Avadel Pharmaceuticals plc and subsidiaries (the Company) and the effectiveness of the Company’s internal control over financial reporting, appearing in this Annual Report on Form 10-K of Avadel Pharmaceuticals plc for the year ended December 31, 2017.
/s/ Deloitte and Touche LLP
St. Louis, Missouri
March 16, 2018